Clinical Trial Update: Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Ubamatamab in combination therapy for adults with platinum-resistant ovarian cancer; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Ubamatamab (ubamatamab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: RECRUITING